Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Novo Nordisk A/S Announces Health Canada Approves Levemir FlexTouch Prefilled Insulin Pen For Treatment Of type 1 And Type 2 Diabetes


Friday, 18 Oct 2013 10:48am EDT 

Novo Nordisk A/S announced that Health Canada has approved Levemir FlexTouch, a disposable prefilled insulin pen containing Levemir (insulin detemir). Levemir FlexTouch has been designed to improve ease of use for insulin administration and to help decrease barriers to good treatment adherence for Canadians living with type 1 and type 2 diabetes mellitus (diabetes). The approval was also announced at the 2013 Vascular Conference in Montreal, Quebec. 

Company Quote

48.31
-0.1 -0.21%
22 Sep 2014